Biotech · Public company · San Diego, CA, US
Neurocrine Biosciences Inc
Ticker NBIX · SEC CIK 0000914475
Track this companyFree. Adds Neurocrine Biosciences Inc to your Dealase workspace and tells you when its record changes.
Clinical trials2516 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline12
- CrinecerfontPhase 3 · Congenital Adrenal HyperplasiaClinicalTrials.gov · fetched Nov 12, 2026
- NBI-1065845Phase 3 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- NBI-1117568Phase 3 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- OsavampatorPhase 3 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- ValbenazinePhase 3 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- ValbenazinePhase 3 · Chorea, HuntingtonClinicalTrials.gov · fetched Nov 12, 2026
- ValbenazinePhase 3 · DyskinesiaClinicalTrials.gov · fetched Nov 12, 2026
- NBI-1065890Phase 2 · Tardive DyskinesiaClinicalTrials.gov · fetched Nov 12, 2026
- NBI-1070770Phase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- NBI-1117568Phase 2 · Bipolar I DisorderClinicalTrials.gov · fetched Nov 12, 2026
- NBI-827104Phase 2 · Epileptic EncephalopathyClinicalTrials.gov · fetched Nov 12, 2026
- NBI-921352Phase 2 · SCN8A Developmental and Epileptic Encephalopathy SyndromeClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Development of Healthcare Transition for Patients With Congenital Adrenal HyperplasiaNOT_YET_RECRUITING · started Jan 1, 2027ClinicalTrials.gov NCT07611786 · fetched Nov 12, 2026
- Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive DyskinesiaPHASE2 · RECRUITING · started Feb 6, 2026ClinicalTrials.gov NCT07365462 · fetched Nov 12, 2026
- An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current ManiaPHASE2 · RECRUITING · started Dec 24, 2025ClinicalTrials.gov NCT07288320 · fetched Nov 12, 2026
- Efficacy of NBI-1117568 in Preventing Relapse in Adults With SchizophreniaPHASE3 · RECRUITING · started Dec 16, 2025ClinicalTrials.gov NCT07227818 · fetched Nov 12, 2026
- A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorPHASE4 · RECRUITING · started Aug 29, 2025ClinicalTrials.gov NCT07105111 · fetched Nov 12, 2026
- A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)PHASE3 · RECRUITING · started Aug 18, 2025ClinicalTrials.gov NCT07196501 · fetched Nov 12, 2026
- NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaPHASE3 · RECRUITING · started Aug 11, 2025ClinicalTrials.gov NCT07105098 · fetched Nov 12, 2026
- NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaPHASE3 · RECRUITING · started Jul 11, 2025ClinicalTrials.gov NCT07114874 · fetched Nov 12, 2026
- NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)PHASE3 · RECRUITING · started May 30, 2025ClinicalTrials.gov NCT06963021 · fetched Nov 12, 2026
- NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaPHASE3 · RECRUITING · started May 8, 2025ClinicalTrials.gov NCT06963034 · fetched Nov 12, 2026
- Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)PHASE3 · RECRUITING · started Apr 16, 2025ClinicalTrials.gov NCT06966401 · fetched Nov 12, 2026
- NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)PHASE3 · RECRUITING · started Mar 31, 2025ClinicalTrials.gov NCT06911112 · fetched Nov 12, 2026
- Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)PHASE3 · RECRUITING · started Jan 22, 2025ClinicalTrials.gov NCT06786624 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive DisorderPHASE2 · COMPLETED · started Mar 20, 2024ClinicalTrials.gov NCT06267846 · fetched Nov 12, 2026
- Efficacy of Valbenazine for the Treatment of Trichotillomania in AdultsPHASE2 · RECRUITING · started Feb 2, 2024ClinicalTrials.gov NCT05207085 · fetched Nov 12, 2026
- Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaPHASE4 · COMPLETED · started May 9, 2023ClinicalTrials.gov NCT05859698 · fetched Nov 12, 2026
- Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEEPHASE2 · TERMINATED · started Jul 12, 2022ClinicalTrials.gov NCT05226780 · fetched Nov 12, 2026
- Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During SleepPHASE2 · TERMINATED · started Jun 7, 2022ClinicalTrials.gov NCT05301894 · fetched Nov 12, 2026
- Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral PalsyPHASE3 · COMPLETED · started Apr 15, 2022ClinicalTrials.gov NCT05206513 · fetched Nov 12, 2026
- Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)PHASE2 · TERMINATED · started Jan 31, 2022ClinicalTrials.gov NCT04873869 · fetched Nov 12, 2026
- Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for SchizophreniaPHASE3 · COMPLETED · started Nov 29, 2021ClinicalTrials.gov NCT05110157 · fetched Nov 12, 2026
- Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)PHASE3 · ACTIVE_NOT_RECRUITING · started Jun 25, 2021ClinicalTrials.gov NCT04806451 · fetched Nov 12, 2026
- Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During SleepPHASE2 · COMPLETED · started Apr 26, 2021ClinicalTrials.gov NCT04625101 · fetched Nov 12, 2026
- Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal HyperplasiaPHASE3 · ACTIVE_NOT_RECRUITING · started Dec 16, 2020ClinicalTrials.gov NCT04490915 · fetched Nov 12, 2026
- Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseasePHASE3 · TERMINATED · started Sep 18, 2020ClinicalTrials.gov NCT04400331 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 28, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Jul 31, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Jul 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 28, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 18, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 6, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 11, 2026 · fetched Nov 12, 2026